Collegium Announces Poster Presentation for Oxycodone DETERx®, a Tamper-Resistant, Extended-Release Opioid at 2012 American Association of Pharmaceutical Scientists Annual Meeting
CUMBERLAND, R.I., Oct. 19, 2012 /PRNewswire/ — Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of a scientific poster titled “Alternate methods of oral administration for Oxycodone DETERx, a novel, extended-release, tamper-resistant opioid formulation” at the 2012 Annual Meeting of the American Association of Pharmaceutical Scientists, held in Chicago, Illinois from October 14-18, 2012. This poster summarized the results for Oxycodone DETERx®, demonstrating that this product may be effectively administered via sprinkling on soft foods or through enteric feeding tubes.
The scientific poster highlighted key findings demonstrating equivalence of in vitro drug release profiles between the oxycodone DETERx® formulation administered as a capsule and alternate routes of administration, including opening the capsule and sprinkling the beads on soft foods or through enteric feeding tubes such as nasogastric or gastronomy tubes.
“These findings confirm that the oxycodone DETERx® formulation may provide a patient benefit not available with other oral extended-release opioids, especially those that have tamper-resistant technologies which make the tablets harder to crush,” said Michael Heffernan, CEO of Collegium. “There are a large number of chronic pain patients, including pediatric and geriatric populations, suffering from dysphagia or in palliative care that may benefit from an extended-release, tamper-resistant oral opioid that can be administered as a sprinkle or through a gastric tube.”
About DETERx® Technology
The DETERx® drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide tamper-resistant properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastronomy tube, while maintaining the extended-release properties of the product. DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx® (COL-003) is the first of a number of product candidates using the DETERx® platform.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides extended-release delivery, unique tamper-resistant properties, and flexible dose administration options. For more information, visit the Company’s website at www.collegiumpharma.com.
Michael Heffernan, President
Collegium Pharmaceutical, Inc.
SOURCE Collegium Pharmaceutical, Inc.